Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
1981–2016
Headlines
3457
Sources here
12
Companies here
26
Current section United States Drug Manufacturers - Specialty & Generic news

Chronological news

Earlier headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Zhengye Biotechnology Holding Ltd (ZYBT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Zhengye Biotechnology Holding Ltd (ZYBT), detailing its support, resistance levels, and performance based on various technical indicators and moving averages. According to the analysis, the overall signal for ZYBT is Neutral, with specific indicators showing mixed signals …

ZYBT main company
Sharemaestro market context Trend signal active 52 weeks -77.7% · Next-week setup negative 43.2% ZYBT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Aquestive Therapeutics (NASDAQ: AQST) will release its second quarter 2026 financial results and provide business updates after market close on August 11, 2026. The company will then host a conference call for investors on August 12, 2026, at 8:00 a.m. ET to discuss these …

AQST main company
Sharemaestro market context Price above Trend Line 52 weeks +6.8% AQST stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Eton seeks FDA expansion of hydrocortisone liquid for children under 5

Eton Pharmaceuticals has submitted a Prior Approval Supplement to the FDA to expand the label of its KHINDIVI oral solution to include pediatric adrenal insufficiency patients under five years old. A new formulation of KHINDIVI demonstrated bioequivalence to an FDA-approved hydrocortisone granule formulation, potentially …

ETON main company
Sharemaestro market context Trend signal active 52 weeks +240.2% · Next-week setup positive 57.2% ETON stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Anika: Q2 Earnings Snapshot

This article provides a second-quarter earnings snapshot for Anika. It contains no financial details or further information about the company's performance. The article is exceptionally brief, offering only a title without substantive content.

ANIK main company
Sharemaestro market context Trend signal active 52 weeks +122.8% ANIK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Anika Therapeutics Q2 revenue rises, lifts 2026 outlook

Anika Therapeutics reported a rise in its second-quarter revenue, leading the company to subsequently lift its financial outlook for 2026. This positive performance and improved forecast were highlighted in a Reuters news brief accessible via TradingView.

ANIK main company
Sharemaestro market context Trend signal active 52 weeks +122.8% ANIK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Evotec SE Sponsored ADR Revenue Breakdown – FWB:EVTA

Evotec SE Sponsored ADR (FWB:EVTA) generated a total revenue of 785.01 million EUR last year. The primary segment contributing to this revenue was Discovery & Preclinical Development, which brought in 508.24 million EUR. The United States was the largest geographical contributor, accounting for 414.63 …

EVO main company
Sharemaestro market context Price below Trend Line 52 weeks -46.2% · Next-week setup negative 42.6% EVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BioXcel Therapeutics Inc (BTAI) Institutional Confidence

This article from TradingKey provides an overview of BioXcel Therapeutics Inc (BTAI)'s institutional confidence, based on an updated score of 3.00 as of July 28, 2026. It details the shares held by various institutional investors and Star Investors, along with the percentage change in …

BTAI main company
Sharemaestro market context Price below Trend Line 52 weeks -76.1% · Next-week setup negative 36.4% BTAI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BioXcel Therapeutics Inc (BTAI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of BioXcel Therapeutics Inc (BTAI), highlighting its current valuation score of 8.84 within the Pharmaceuticals industry. It also details the company's P/E ratio, noting that other relevant financial data such as P/B, P/S, and P/CF have not yet …

BTAI main company
Sharemaestro market context Price below Trend Line 52 weeks -76.1% · Next-week setup negative 36.4% BTAI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch

Viatris Inc. announced that the U.S. FDA has approved Gwyn Lo™, a new once-weekly combined hormonal contraceptive patch. This low-dose estrogen patch is indicated for women of childbearing potential with a BMI below 30 kg/m² and demonstrated efficacy and a well-characterized safety profile in …

VTRS main company
Sharemaestro market context Trend signal active 52 weeks +56.5% VTRS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution

Eton Pharmaceuticals has submitted a Prior Approval Supplement to the FDA to expand the indication of KHINDIVI (hydrocortisone) oral solution to include younger pediatric patients. The new formulation demonstrated bioequivalence to ALKINDI SPRINKLE, and the company anticipates potential approval in the first half of …

ETON main company
Sharemaestro market context Trend signal active 52 weeks +240.2% · Next-week setup positive 57.2% ETON stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Collegium Pharmaceutical Inc (COLL) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Collegium Pharmaceutical Inc (COLL), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 7.30, ranking 37 out of 155 in the Pharmaceuticals industry, with a beta of 0.75 indicating underperformance …

COLL main company
Sharemaestro market context Price below Trend Line 52 weeks -27.8% COLL stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Supernus Pharmaceuticals Inc (SUPN) Financial Health: Profitability & Balance Sheet Analysis

Supernus Pharmaceuticals Inc (SUPN) currently holds a financial score of 7.52, ranking 111th out of 155 in the Pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company recently reported a quarterly revenue of $207.71 million, marking a 38.63% year-over-year increase, and …

SUPN main company
Sharemaestro market context Price below Trend Line 52 weeks +7.6% SUPN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Elanco Animal Health Incorporated $ELAN is Redwood Grove Capital LLC's Largest Position

Redwood Grove Capital LLC maintains Elanco Animal Health Incorporated ($ELAN) as its largest position, despite reducing its stake by 17% in the first quarter, holding 1.29 million shares valued at approximately $30.9 million. This represents about 10% of Redwood Grove Capital's portfolio. Institutional ownership …

ELAN main company
Sharemaestro market context Price below Trend Line 52 weeks +32.2% ELAN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Teva Pharmaceutical Industries (NYSE: TEVA) Q2 loss while raising brand outlook

Teva Pharmaceutical Industries reported a Q2 2026 GAAP net loss of $576 million but maintained its full-year revenue and free cash flow guidance, while raising the outlook for its key innovative brands (AUSTEDO, AJOVY, and UZEDY) to approximately $3.7 billion. The loss was primarily …

TEVA main company
Sharemaestro market context Trend signal active 52 weeks +99.2% · Next-week setup positive 56.3% TEVA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BIOA|BIOAGE Labs Inc|Price:21.950|Chg%:+1.070

This article provides a comprehensive stock analysis of BIOAGE Labs Inc (BIOA) by TradingKey, highlighting its strong fundamentals, high growth potential, and "Buy" rating from analysts with a target price of $42.88. The company is in a growing phase, has high profit growth, and …

BIOA main company
Sharemaestro market context Price below Trend Line 52 weeks +129.9% · Next-week setup positive 65.7% BIOA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Evotec Number of Employees 2026 | Employee Count & Headcount Data

Evotec SE (XETRA: EVT) had approximately 4,535 employees worldwide as of March 2026, marking a 7.3% decline from 2023 but a 0.4% increase year-over-year in 2026. The company is actively hiring with 142 job postings in 2026. The workforce is concentrated in the UK, …

EVO main company
Sharemaestro market context Price below Trend Line 52 weeks -46.2% · Next-week setup negative 42.6% EVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AKBA|Akebia Therapeutics Inc|Price:1.275|Chg%:-0.005

Akebia Therapeutics Inc (AKBA) has a healthy fundamental outlook and high growth potential, with its valuation considered fairly valued. Despite strong analyst ratings with a "Strong Buy" consensus and a high institutional ownership, the stock is currently trading sideways. The company is a biopharmaceutical …

AKBA main company
Sharemaestro market context Price below Trend Line 52 weeks -72.6% AKBA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet

United Therapeutics announced that the ADVANCE OUTCOMES study of ralinepag for pulmonary arterial hypertension (PAH) has been published in The Lancet. The study, which included predominantly pre-treated patients, met its primary endpoint by reducing the risk of a clinical worsening event by 55% compared …

UTHR main company
Sharemaestro market context Trend signal ended 52 weeks +60.1% · Next-week setup positive 58.0% UTHR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

How Collegium's Quarterly Beat but Softer Outlook Could Reframe Collegium Pharmaceutical (COLL) Investors

Collegium Pharmaceutical reported strong quarterly revenue and earnings that exceeded analyst estimates, but its full-year guidance was softer than expected. This divergence highlights investor focus on how the company's management views its medium-term growth and product momentum, especially given its concentrated portfolio in pain …

COLL main company
Sharemaestro market context Price below Trend Line 52 weeks -27.8% COLL stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Indivior PLC (INDV) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Indivior PLC (INDV), highlighting its strong valuation score of 9.73, which ranks it highly within the Pharmaceuticals industry. It details the company's current P/E ratio, its market capitalization, and stock performance, while noting that data for P/B, …

INDV main company
Sharemaestro market context Trend signal active 52 weeks +60.4% INDV stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: Should You Buy?

Elanco Animal Health (ELAN) is expected to report a year-over-year increase in earnings and revenues for the quarter ended June 2026. The company has a Zacks Earnings ESP of +3.16% and a Zacks Rank #2 (Buy), suggesting a high probability of an earnings beat. …

ELAN main company
Sharemaestro market context Price below Trend Line 52 weeks +32.2% ELAN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Talphera, Inc. Revenue Breakdown – MUN:R5XA

Talphera, Inc. (MUN:R5XA) generated a total revenue of 23.84K EUR last year, a significant decrease from 589.81K EUR in the previous year. The "Innovative Therapies" segment was the primary revenue driver, accounting for all 23.84K EUR. The United States was the sole geographical contributor …

TLPH main company
Sharemaestro market context Trend signal active 52 weeks +149.6% · Next-week setup negative 38.8% TLPH stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Evolus Inc (EOLS), detailing its price movement, support and resistance levels, and insights from various technical indicators and moving averages. The stock currently has a price momentum score of 4.73 and is trading between a resistance of …

EOLS main company
Sharemaestro market context Trend signal active 52 weeks +6.2% EOLS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Evolus Inc (EOLS) Institutional Confidence

The article provides an overview of Evolus Inc's institutional confidence, detailing its current score, industry ranking, and institutional shareholding proportion, which has decreased by 14.84% quarter-over-quarter. It lists key institutional shareholders and their recent activity. The institutional shareholding score for EOLS is 7.00, placing …

EOLS main company
Sharemaestro market context Trend signal active 52 weeks +6.2% EOLS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Cumberland Pharmaceuticals Inc (CPIX) Institutional Confidence

The article provides an institutional confidence score for Cumberland Pharmaceuticals Inc (CPIX), which currently stands at 3.00, ranking 92 out of 155 in the Pharmaceuticals industry. It highlights that the institutional shareholding proportion is 19.66%, a 30.06% decrease quarter-over-quarter. James Simons is identified as …

CPIX main company
Sharemaestro market context Trend signal active 52 weeks +136.8% CPIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Amphastar Sets Aug. 6 Webcast for Second-Quarter Results

Amphastar Pharmaceuticals (NASDAQ: AMPH) announced it will release its second-quarter 2026 financial results on Thursday, August 6, 2026, after the market closes. The company will also host a conference call at 2:00 p.m. Pacific Time to discuss the results, with access available via dial-in …

AMPH main company
Sharemaestro market context Price below Trend Line 52 weeks -31.4% AMPH stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Kamada Ltd (KMDA) Financial Health: Profitability & Balance Sheet Analysis

Kamada Ltd (KMDA) has a stable financial score of 7.95, ranking 90th in the Pharmaceuticals industry, indicating high operating efficiency. The company recently reported a 2.78% year-over-year increase in quarterly revenue to $45.24 million and a 4.24% rise in net profit. However, specific detailed …

KMDA main company
Sharemaestro market context Price below Trend Line 52 weeks +8.8% KMDA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AYTU|Aytu Biopharma Inc|Price:2.135|Chg%:+0.075

This article provides a detailed financial overview of Aytu Biopharma Inc. (AYTU), including its latest earnings report from May 13, 2026, and historical quarterly and annual financial indicators. It covers key metrics such as EPS, revenue, net profit, margins, debt-to-assets ratio, and various balance …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Cronos Group Inc (CRON) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Cronos Group Inc (CRON), indicating a current earnings forecast score of 7.00, ranking 112 out of 155 in the Pharmaceuticals industry. Based on 2 analysts, the stock has an average price target of $2.90 and a "Buy" …

CRON main company
Sharemaestro market context Trend signal active 52 weeks +20.8% CRON stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Talphera Inc (TLPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Talphera Inc (TLPH), detailing its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. The stock currently ranks 17th in the Pharmaceuticals industry for price momentum, and its price is …

TLPH main company
Sharemaestro market context Trend signal active 52 weeks +149.6% · Next-week setup negative 38.8% TLPH stored weekly price path from 22 Aug 2025 to 14 Aug 2026

SIGA Technologies Inc Today's Market Trends | SIGA Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey

This article provides an in-depth analysis of SIGA Technologies Inc. (SIGA) stock, including real-time quotes, market trends, key financials, and trading strategies. It highlights the company's strong fundamentals and growth potential, despite recent stock market performance, and details its flagship product, TPOXX, an antiviral …

SIGA main company
Sharemaestro market context Price below Trend Line 52 weeks -62.8% SIGA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Perrigo Company PLC (PRGO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Perrigo Company PLC (PRGO), noting its current valuation score is 8.65, ranking 75th in the Pharmaceuticals industry. The article highlights the company's current P/E ratio and mentions that relevant data for P/B, P/S, and P/CF ratios have …

PRGO main company
Sharemaestro market context Price above Trend Line 52 weeks -42.2% PRGO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Cronos Group Inc Revenue Breakdown – GETTEX:7CI

Cronos Group Inc. (7CI) generated €124.81 million in revenue last year, with its Cannabis Flower segment being the main contributor at €93.98 million. The majority of this revenue, €78.25 million, came from the Canadian market. This highlights the company's reliance on its cannabis flower …

CRON main company
Sharemaestro market context Trend signal active 52 weeks +20.8% CRON stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Emergent BioSolutions Inc (EBS) Institutional Confidence

Emergent BioSolutions Inc (EBS) has an institutional shareholding score of 7.00, placing it 50th out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion is 81.98%, a slight decrease quarter-over-quarter. James Simons is the largest institutional shareholder, with other significant holders including BlackRock …

EBS main company
Sharemaestro market context Price below Trend Line 52 weeks -50.3% · Next-week setup negative 43.4% EBS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership reduced its stake in Kiniksa Pharmaceuticals International (NASDAQ:KNSA) by 16.4% in the first quarter, selling 175,550 shares and retaining 892,666 shares valued at $42,982,000. Other institutional investors also adjusted their holdings, while company insiders, including a CEO and an insider, …

KNSA main company
Sharemaestro market context Trend signal active 52 weeks +127.4% · Next-week setup positive 55.5% KNSA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Perrigo to Present at the Canaccord 46th Annual Growth Conference

Perrigo Company plc announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra will present at the Canaccord 46th Annual Growth Conference on August 12th at 10:30 AM EDT. The presentation will be webcast live on the company's investor relations website. Perrigo, …

PRGO main company
Sharemaestro market context Price above Trend Line 52 weeks -42.2% PRGO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context